Skip to main content
Fig. 3 | Molecular Brain

Fig. 3

From: A mutant vesicular stomatitis virus with reduced cytotoxicity and enhanced anterograde trans-synaptic efficiency

Fig. 3

Analysis of inflammatory responses induced by WT-VSV and Mutant-VSV at injection site. a-c Immunostaining for the microglial marker Iba1 at injection site. Iba1-positive cells were observed in the WT-VSV group at 1 DPI, but barely in the Mutant-VSV or PBS injected (Mock) DG. d-f Intense microglial activation was observed at the injection site when WT-VSV or Mutant-VSV was injected into the DG at 3 DPI, and signals in the WT-VSV group were more than that in the Mutant-VSV group, while few signals were observed in the PBS injected (Mock) DG. g Quantification of mean fluorescence intensity (Mean ± SEM) of Iba1 in DG at 1 DPI. Mutant-VSV: 9.251 ± 0.182, WT-VSV: 16.02 ± 0.9505, Mock: 8.22 ± 0.4402, Mutant-VSV vs Mock: P = 0.0963; WT-VSV vs Mock: P = 0.0017; WT-VSV vs Mutant-VSV: P = 0.0022; n = 3. h Quantification of mean fluorescence intensity (Mean ± SEM) of Iba1 in DG at 3 DPI. Mutant-VSV: 16.29 ± 0.7438, WT-VSV: 23.41 ± 1.836, Mock: 9.828 ± 0.7976, Mutant-VSV vs Mock: P = 0.0041; WT-VSV vs Mock: P = 0.0025; WT-VSV vs Mutant-VSV: P = 0.0229; n = 3. n is mice number. Scale bars = 200 μm for A-F. Unpaired t-tests, *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page